(Q48576993)

12 February 2018

title

Changes in adiponectin and the risk of sudden death, stroke, myocardial infarction, and mortality in hemodialysis patients. (English)

1 reference

12 February 2018

main subject

patient

0 references

myocardial infarction

1 reference

1 reference

Friedo W Dekker

4

0 references

author name string

Christiane Drechsler

1

1 reference

12 February 2018

Vera Krane

2

1 reference

12 February 2018

Karl Winkler

3

1 reference

12 February 2018

Christoph Wanner

5

1 reference

12 February 2018

language of work or name

English

0 references

publication date

10 June 2009

1 reference

12 February 2018

published in

Kidney International

1 reference

12 February 2018

volume

76

1 reference

12 February 2018

issue

5

1 reference

12 February 2018

page(s)

567-575

1 reference

12 February 2018

https://scigraph.springernature.com/pub.10.1038/ki.2009.200

exact match

0 references

cites work

Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.200

7 January 2021

Inverse relationship between plasma adiponectin and leptin concentrations in normal-weight and obese women

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.200

7 January 2021

The adipocyte-secreted protein Acrp30 enhances hepatic insulin action

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.200

7 January 2021

The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.200

7 January 2021

Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.200

7 January 2021

The emerging biology of adipose tissue in chronic kidney disease: from fat to facts

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.200

7 January 2021

Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.200

7 January 2021

Association of hypoadiponectinemia with coronary artery disease in men

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.200

7 January 2021

Plasma adiponectin levels and risk of myocardial infarction in men.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.200

7 January 2021

Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.200

7 January 2021

Adiponectin and mortality in patients with chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.200

7 January 2021

Gender-specific association of adiponectin as a predictor of progression of chronic kidney disease: the Mild to Moderate Kidney Disease Study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.200

7 January 2021

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.200

7 January 2021

Adiponectin in peritoneal dialysis patients: a comparison with hemodialysis patients and subjects with normal renal function

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.200

7 January 2021

Adiponectin and Renal Function, and Implication as a Risk of Cardiovascular Disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.200

7 January 2021

Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.200

7 January 2021

Excerpts from the United States Renal Data System 2007 annual data report.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.200

7 January 2021

Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.200

7 January 2021

Association between Body Mass Index and Mortality Is Similar in the Hemodialysis Population and the General Population at High Age and Equal Duration of Follow-Up

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.200

7 January 2021

Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.200

7 January 2021

Adiponectin acts in the brain to decrease body weight.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.200

7 January 2021

Weight Reduction Increases Plasma Levels of an Adipose-Derived Anti-Inflammatory Protein, Adiponectin

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.200

7 January 2021

Adiponectin is associated with brain natriuretic peptide and left ventricular hypertrophy in hemodialysis patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.200

7 January 2021

Plasma adiponectin is associated with plasma brain natriuretic peptide and cardiac function in healthy subjects

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.200

7 January 2021

Association of adiponectin with adverse outcome in coronary artery disease patients: results from the AtheroGene study.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.200

7 January 2021

Increased adiponectin level in parallel with increased NT-pro BNP in patients with severe heart failure in the elderly: A hospital cohort study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.200

7 January 2021

Effect of atrial natriuretic peptide on adiponectin in patients with heart failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.200

7 January 2021

Change in N-terminal-pro-B-type-natriuretic-peptide and the risk of sudden death, stroke, myocardial infarction, and all-cause mortality in diabetic dialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.200

7 January 2021

Plasma adiponectin levels and clinical outcomes among haemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.200

7 January 2021

Adiponectin is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction in patients presenting with chest pain

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.200

7 January 2021

Adiponectin and mortality in patients undergoing coronary angiography.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.200

7 January 2021

Sudden cardiac death and dialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.200

7 January 2021

The challenge of sudden death in dialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.200

7 January 2021

Adiponectin as an anti-inflammatory factor

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.200

7 January 2021

AMPK inhibits fatty acid-induced increases in NF-kappaB transactivation in cultured human umbilical vein endothelial cells.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.200

7 January 2021

Adiponectin decreases C-reactive protein synthesis and secretion from endothelial cells: evidence for an adipose tissue-vascular loop

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.200

7 January 2021

Adiponectin inhibits endothelial synthesis of interleukin-8.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.200

7 January 2021

Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.200

7 January 2021

Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.200

7 January 2021

Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.200

7 January 2021

Adiponectin modulates inflammatory reactions via calreticulin receptor-dependent clearance of early apoptotic bodies.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.200

7 January 2021

A blast from the past: clearance of apoptotic cells regulates immune responses.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.200

7 January 2021

Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.200

7 January 2021

Inflammation enhances cardiovascular risk and mortality in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.200

7 January 2021

Adiponectin circulating levels: a new emerging biomarker of cardiovascular risk.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.200

7 January 2021

Selective increase in high molecular weight adiponectin concentration in serum of women with preeclampsia

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.200

7 January 2021

Total and high molecular weight adiponectin, haemodynamics, and mortality in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.200

7 January 2021

Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.200

7 January 2021

Confounding: What it is and how to deal with it

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.200

7 January 2021

Identifiers

DOI

10.1038/KI.2009.200

1 reference

12 February 2018

1 reference

12 February 2018